#3 - Eli Lilly (NYSE:LLY)
Pharmaceutical stocks are solid defensive stocks at any time. However, the case for Eli Lilly and Company (NYSE: LLY) has an additional tailwind. That comes from the company’s blockbuster products in the GLP-1 arena, Mounjaro and Zepbound.
Mounjaro is a groundbreaking treatment for Type-2 diabetes and Zepbound is Lilly’s entry into the booming market for obesity treatment. Individuals may cut back on many things if inflation heats up, but they will always make room for their prescriptions. That’s particularly true of both Mounjaro and Zepbound, which patients need to continue taking to maintain the benefits.
Through the third quarter of the company’s 2024 fiscal year, Eli Lilly has generated a non-GAAP gross margin of 83%, which is higher than the sector average. And the company has a deep pipeline of products, including in the critical area of oncology, that will continue to help the company grow revenue and earnings well into the future. LLY stock also pays a dividend, which it has increased for 11 consecutive years as of January 2025.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $741.98
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1,002.22 (35.1% Upside)
